In summary, our study establishes CLR and LDH as clinically accessible biomarkers that predict survival heterogeneity in PD-L1-negative NSCLC patients receiving the BRICS sequential regimen. This evidence concerns the gene DCLK3 and non-small cell lung carcinoma.